By Evercyte GmbH
To get in touch with Evercyte GmbH, simply fill out the form below.
Subscribe to Supplier
Evercyte bringing EV partnership opportunities to BIO-Europe Spring online summit
Vienna, Austria: – Innovative biotech manufacturer Evercyte will be returning to Europe’s key pharma partnering event, BIO-Europe, now re-imagined as a fully digitally delivered online networking summit.
Evercyte CEO Dr. Otto Kanzler and Chief Operations Officer/Chief Scientific Officer Dr. Regina Grillari, will head the company’s presence at BIO Europe Spring 2022.
Evercyte has maintained a long-standing association with BIO Europe series that form valuable platform’s for strengthening and deepening its customer and partnership connections.
Focus on EV production partnerships
At BIOEurope Spring 2022, Evercyte will be talking about its expanding range of cell based assays; senolytic and senomorphic drug testing and extracellular vesicle (EV) related services including EV potency assays, enrichment and purification, and characterization.
The Evercyte team is particularly keen to talk to potential partners for production of clinical-grade EVs for therapeutic applications, based on its proprietary EV cell factories. These include use of mesenchymal stromal/stem cells (MSCs) from different tissues and organs including bone-marrow, adipose tissue, placenta, amnion, dental pulp, and endometrium.
Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel production cell lines for extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.
The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalog of readily available cell lines for the production of extracellular vesicles from mesenchymal stem cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.
By providing native extracellular vesicles from mesenchymal stem cells and targeting extracellular vesicles Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs for e.g. tissue targeting and drug targeting.
Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in-vitro bioassays as well as relevant cell models and cell factories.
Learn more at: http://www.evercyte.com.
About BIO Europe Spring 2022
The biannual BIO-Europe events are premier partnering conferences dedicated to driving forward partnering in the life sciences sector. They attract an international “who’s who” from biotech, pharma and finance for high caliber networking.
BIO-Europe Spring is being delivered digitally as a four-day online event, opening March 28. This will use forums, webinars and video conferencing technology to allow the same networking and knowledge sharing benefits as the ‘live’ event, along with the sophisticated partneringONE® platform to enable networking and meetings between financiers, innovators and companies across the life science value chain, from large biotech to start-ups.
BIO Europe Spring will feature more than 2,700 assets posted online and representations from more than 50 countries worldwide.
BIO Europe DIGITAL is organized by the EBD Group in association with the Washington DC-based Biotechnology Innovation Organization. Further information at: https://informaconnect.com/bioeurope-spring/
Click on News from Evercyte for more recent developments.